In recent years, domestic pharmaceutical enterprises have been continuously entering overseas markets through acquisitions or cooperation, involving tens of billions of yuan every year, and the target assets include pharmaceutical companies, health care product enterprises, hospitals, research institutions, etc
.
This year, the mergers and acquisitions of overseas pharmaceutical companies by local pharmaceutical companies have also continued to increase
.
For example, last week, Fosun Pharma announced that GlandPharma and its holding subsidiary, GlandIntl.
, intend to purchase 99.
84% of the equity of French CDMO company Cenexi Group and provide it with shareholder loans, and the total amount of transfer consideration and shareholder borrowings will not exceed 2.
1 euros, or about 1.
55 billion yuan
.
Through this transaction, GlandPharma will gain access to local production sites in Europe and expand its capabilities
.
Fosun Pharma will use GlandPharma to accelerate its transformation
into biological CDMOs, complex preparations and difficult injections.
The industry generally believes that this acquisition is a reflection of Fosun Pharma's acceleration of
global market layout.
It is reported that on June 6, Fosun Pharma also announced that FosunPharmaPte.
, the company's holding subsidiary, intends to invest no more than S$217 million to acquire 60% of the equity
of OncoCare held by SolidSuccess, SMS and three holding doctors.
It is reported that OncoCare is currently a large private oncology specialist medical center
with a large number of local oncologists in Singapore.
It is worth mentioning that this year, under the background of Fosun Pharma's continuous acceleration of the pace of international development, its overseas revenue has grown
strongly.
According to the financial report, in the first half of 2022, Fosun Pharma's overseas revenue was 7.
592 billion yuan, a year-on-year increase of 46.
06%, and its revenue accounted for 35.
58%, an increase of 4.
92 percentage points
over the same period last year.
In this regard, Fosun Pharma said that it was mainly due to the strong growth
of Sisram's business in major markets such as North America and Europe.
In addition to Fosun Pharma, in July this year, WuXi AppTec and WuXi Biologics also announced that they plan to build a new R&D and production base
in Singapore with S$2 billion, or about 9.
9 billion yuan, in the next ten years.
In June, China Biopharma announced that the Company, its wholly-owned subsidiary invoX Pharma Limited and Fennec Acquisition Incorporated, a wholly-owned subsidiary of invoX, entered into a merger agreement and plan with F-star Therapeutics, Inc.
to acquire F-star Therapeutics for more than US$160 million to further complement the
。
In addition, as early as January 10, Kanglong Chemical announced the successful acquisition of Aesica Pharmaceuticals in Cramlington, UK, a subsidiary of Recipharm, to further enhance the overall strength
of the small molecule CDMO service platform.
.
.
.
.
.
.
.
In general, the acquisition of overseas companies has become the choice
of more and more Chinese pharmaceutical companies.
The industry believes that under the general trend of innovation, domestic pharmaceutical companies choose to acquire overseas pharmaceutical companies with R&D and production strength, which can quickly broaden their product lines, cut into new fields, and accelerate the pace of
international development.
In the future, it is expected that more and more Chinese pharmaceutical companies will promote the internationalization of enterprises through acquisitions, graft foreign advanced technologies, and continuously improve their competitiveness
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
